Role of EPO and TCF7L2 Gene Polymorphism Contribution to the Occurrence of Diabetic Retinopathy

Table 5

Frequences of genotypes and alleles of EPO and TCF7L genes polymorphisms in normal controls and diabetes mellitus patients.

SNP	Genotype	Normal controls (%)	DM (%)	value	OR (95% CI)
	Allele	()			()
	AA	(56.60%) 133	(63.20%) 79	0.225	0.759 (0.486-1.186)
	AC	(40.00%) 94	(30.40%) 38	0.072	1.526 (0.962-2.422)
rs551238; (EPO1)	CC	(3.4%) 8	(6.40%) 8	0.189	0.515 (0.189-1.408)
	A	(95.60%) 227	(93.60%) 117	0.583	0.902 (0.623-1.304)
	C	(47.66.4%) 112	(36.80%) 46	0.583	1.109 (0.767-1.604)
	GG	(2.98%) 7	(3.20%) 4	0.908	0.929 (0.627-3.235)
	GT	(36.17%) 85	(29.60%) 37	0.148	1.409 (0.885-2.244)
rs1617640; (EPO 2)	TT	(60.85%) 143	(67.20%) 84	0.235	0.759 (0.481-1.197)
	G	(39.15%) 92	(32.80%) 41	0.328	1.216 (0.822-1.798)
	T	(97.02%) 228	(96.80%) 121	0.328	0.823 (0.556-1.217)
	CC	(94.89%) 223	(96.00%) 120	0.638	0.774 (0.266-2.250)
	CT	(5.11%) 12	(4.00%) 5	0.638	1.291 (0.444-3.725)
rs7903146; (TCF7L2)	TT	(0) 0	(0) 0
	C	(100.00%) 235	(100.00%) 125	0.642	0.779 (0.271-2.236)
	T	(5.11%) 12	(4.00%) 5	0.642	1.284 (0.447-3.686)